



May 12, 2022

## Terumo Announces Dividends for Fiscal Year Ended March 31, 2022 (Increased payment)

TOKYO, JAPAN – May 12, 2022 – Terumo Corporation (TSE: 4543) announced today it has approved the dividends for fiscal year ended March 31, 2022 at its Board of Directors meeting held on May 12, 2022.

### 1. Details of Dividends

	Decided dividends	Latest dividends forecast (As of November 4, 2021)	FY2021 dividends (Actual)
Record date	March 31, 2022	March 31, 2022	March 31, 2021
Dividends per share	18.0JPY	16.0JPY	15.0JPY
Total amount of dividends	13,613 million JPY	-	11,340 million JPY
Dividends payment starting date	June 23, 2022	-	June 23, 2021
Source of dividends	Retained earnings	-	Retained earnings

### 2. Reason

As a measure to secure high profit margins and sustainable growth, Terumo is committed to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo will continually aim to steadily increase its dividend payouts to shareholders and has set a mid to long term dividend payout ratio target of 30%.

Based on the above policy and financial results, the company decided the year-end dividends of 18.0JPY per share and the annual dividends for the year amounts to 34.0JPY per share. The revised dividends for the year-end will be adopted on the condition of approval from shareholders in the general shareholders' meeting to be held on June 22, 2022.

### (Reference) Dividend Breakdown

Record date	Dividends per share		
	Interim dividends	Year-end dividends	Annual dividends (Total)
FY2022 (Ended March 31, 2022)	16.0JPY	18.0JPY	34.0JPY
FY2021 (Ended March 31, 2021)	14.0JPY	15.0JPY	29.0JPY

**About Terumo Corporation**

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

**Disclaimer**

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.